SI-BONE (SIBN) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
4 Jun, 2026Opening remarks and agenda
Meeting commenced at 8:00 A.M. Pacific Time on June 4th, 2026, via a virtual platform.
Board members, executive officers, independent auditor, and legal counsel were introduced.
The agenda included three proposals: election of directors, ratification of auditor, and advisory vote on executive compensation.
Corporate governance
Inspector of Election appointed to oversee voting and ensure impartiality.
Quorum established with proxies for 87.93% of outstanding shares.
Stockholder list and notice of meeting were made available and certified.
Shareholder proposals
Election of two directors to serve until the 2029 annual meeting.
Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation as disclosed in the proxy statement.
Latest events from SI-BONE
- Q2 2026 saw 15.2% revenue growth, improved profitability, and raised full-year guidance.SIBN
Q2 2026 - Record revenue, expanding physician base, and new products set up EBITDA breakeven in Q4 2024.SIBN
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 - Multi-product innovation, expanded partnerships, and reimbursement tailwinds set up multi-year growth.SIBN
Truist Securities MedTech Conference 2026 - Innovation, partnerships, and reimbursement changes set the stage for multi-year growth acceleration.SIBN
Bank of America Global Healthcare Conference 2026 - Double-digit growth, record profitability, and innovation drive expansion in a $3.5B+ market.SIBN
Corporate presentation - Q1 2026 saw 11.2% revenue growth, margin strength, and raised full-year guidance.SIBN
Q1 2026 - Strong revenue growth, improved profitability, and robust governance mark this year's proxy.SIBN
Proxy filing - Q3 2024 revenue up 19% to $40.3M, net loss narrows, and Adjusted EBITDA nears breakeven.SIBN
Q3 2024 - Record revenue and positive Adjusted EBITDA support strong 2025 growth outlook.SIBN
Q4 2024